Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NKTR-102

- PMLiVE

New data advances AstraZeneca’s “revolution in oncology”

In a busy few weeks for AstraZeneca, the company will present data on 14 approved and potential drugs in lung and breast cancer

Roche Basel Switzerland

Tecentriq withdrawn in hard-to-treat breast cancer in US

A post-marketing study failed to show benefit for patients with triple-negative breast cancer taking Tecentriq and chemotherapy

- PMLiVE

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer

- PMLiVE

Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO

Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%

- PMLiVE

Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO

Lynparza reduced the risk of invasive breast cancer recurrence, second cancers or death by 42% in the overall trial population

- PMLiVE

Novartis’ Kisqali shows long-term improvements in breast cancer patients

Data shows the ‘longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients’

- PMLiVE

UK approval for Seagen’s oral HER2 inhibitor Tukysa

MHRA has authorised drug for HER2-positive advanced breast cancer

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

- PMLiVE

Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu

- PMLiVE

Google’s DeepMind AI outperforms doctors on breast cancer screening

System reduced false positive and false negative decisions

Roche Basel Switzerland

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Could face tough competition soon from a number of rivals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links